1. Home
  2. AYTU vs APCX Comparison

AYTU vs APCX Comparison

Compare AYTU & APCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • APCX
  • Stock Information
  • Founded
  • AYTU N/A
  • APCX 2006
  • Country
  • AYTU United States
  • APCX United States
  • Employees
  • AYTU N/A
  • APCX N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • APCX Finance: Consumer Services
  • Sector
  • AYTU Health Care
  • APCX Finance
  • Exchange
  • AYTU Nasdaq
  • APCX Nasdaq
  • Market Cap
  • AYTU 15.0M
  • APCX 15.2M
  • IPO Year
  • AYTU N/A
  • APCX N/A
  • Fundamental
  • Price
  • AYTU $2.25
  • APCX $0.68
  • Analyst Decision
  • AYTU
  • APCX
  • Analyst Count
  • AYTU 0
  • APCX 0
  • Target Price
  • AYTU N/A
  • APCX N/A
  • AVG Volume (30 Days)
  • AYTU 31.2K
  • APCX 272.6K
  • Earning Date
  • AYTU 11-12-2024
  • APCX 11-12-2024
  • Dividend Yield
  • AYTU N/A
  • APCX N/A
  • EPS Growth
  • AYTU N/A
  • APCX N/A
  • EPS
  • AYTU N/A
  • APCX N/A
  • Revenue
  • AYTU $81,002,000.00
  • APCX $462,000.00
  • Revenue This Year
  • AYTU N/A
  • APCX $1,315.48
  • Revenue Next Year
  • AYTU N/A
  • APCX N/A
  • P/E Ratio
  • AYTU N/A
  • APCX N/A
  • Revenue Growth
  • AYTU N/A
  • APCX 3.59
  • 52 Week Low
  • AYTU $2.16
  • APCX $0.44
  • 52 Week High
  • AYTU $3.50
  • APCX $3.27
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 42.97
  • APCX 51.23
  • Support Level
  • AYTU $2.11
  • APCX $0.55
  • Resistance Level
  • AYTU $2.44
  • APCX $0.62
  • Average True Range (ATR)
  • AYTU 0.14
  • APCX 0.06
  • MACD
  • AYTU -0.02
  • APCX 0.02
  • Stochastic Oscillator
  • AYTU 22.30
  • APCX 94.16

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.

About APCX AppTech Payments Corp.

AppTech Payments Corp is a FinTech company utilizing various payment processing and digital banking technologies to complement core merchant services capabilities. The company's patented and proprietary software will provide progressive and adaptable products that are available through a suite of synergistic offerings directly to merchants, banking institutions, and business enterprises. It is developing a secure digital payments and banking platform that powers commerce experiences for clients and customers. Based upon industry standards for payment and banking protocols, the company will offer standalone products and fully integrated solutions that deliver unparalleled payments, banking, and financial services experiences.

Share on Social Networks: